Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review
Open Access
- 1 January 2020
- journal article
- review article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (7), 1591-1610
- https://doi.org/10.3906/sag-2008-11
Abstract
Familial Mediterranean fever (FMF) (OMIM #249100) is the most common hereditary autoinflammatory disease in the world. FMF is caused by gain of function mutations of MEFV gene which encodes an immune regulatory protein, pyrin. Over the last few years, we have witnessed several new developments in the pathogenesis, genetic testing, diagnosis, comorbidities, disease related damage and treatment approaches to FMF. Elucidation of some of the pathogenic mechanisms has led to the discovery of pathways involved in inflammatory, metabolic, cardiovascular and degenerative diseases. The use of next generation sequencing in FMF has revealed many new gene variants whose clinical significance may be clarified by developing functional assays and biomarkers. Clinically, although IMF is considered an episodic disease characterized by brief attacks, recent systematic studies have defined several associated chronic inflammatory conditions. Colchicine is the mainstay of FMF treatment, and interleukin (IL)-1 antagonists are the treatment of choice in refractory or intolerant cases. Experience of IL-1 antagonists, anakinra and canakinumab, is now available in thousands of colchicine resistant or intolerant FMF patients. In this contemporary review, we surveyed current FMF knowledge in the light of these recent advances.Keywords
This publication has 153 references indexed in Scilit:
- Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromesAnnals Of The Rheumatic Diseases, 2013
- Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in childrenAnnals Of The Rheumatic Diseases, 2013
- Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failureNephrology Dialysis Transplantation, 2011
- Analysis of MEFV exon methylation and expression patterns in familial Mediterranean feverBMC Medical Genetics, 2011
- Familial mediterranean fever with a single MEFV mutation: Where is the second hit?Arthritis & Rheumatism, 2009
- In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromesThe Journal of Experimental Medicine, 2009
- The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitisClinical Rheumatology, 2008
- The spectrum of Familial Mediterranean Fever (FMF) mutationsEuropean Journal of Human Genetics, 2001
- Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases?Medical Hypotheses, 1998
- Colchicine in the Prevention and Treatment of the Amyloidosis of Familial Mediterranean FeverThe New England Journal of Medicine, 1986